Equities

Beam Therapeutics Inc

BEAM:NSQ

Beam Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)25.05
  • Today's Change1.47 / 6.23%
  • Shares traded1.19m
  • 1 Year change-15.00%
  • Beta1.8605
Data delayed at least 15 minutes, as of Nov 22 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
  • 21-Nov-24
Select bar for recommendation details.
Recommendations21-Nov-24
Buy6
Outperform4
Hold8
Sell0
Strong Sell0

Share price forecast in USD

The 14 analysts offering 12 month price targets for Beam Therapeutics Inc have a median target of 49.00, with a high estimate of 80.00 and a low estimate of 23.00. The median estimate represents a 95.61% increase from the last price of 25.05.
High219.4%80.00
Med95.6%49.00
Low-8.2%23.00

Earnings history & estimates in USD

On Nov 05, 2024, Beam Therapeutics Inc reported 3rd quarter 2024 losses of -1.17 per share. This result was in line with the consensus of the 16 analysts following the company and exceeded last year's 3rd quarter results by 4.10%.
The next earnings announcement is expected on Feb 25, 2025.
Average growth rate+1.43%
Beam Therapeutics Inc reported annual 2023 losses of -1.72 per share on Feb 27, 2024.
Average growth rate+29.81%
More ▼

Revenue history & estimates in USD

Beam Therapeutics Inc. had 3rd quarter 2024 revenues of 14.27m. This missed the 14.50m consensus estimate of the 16 analysts following the company. This was 41.06% below the prior year's 3rd quarter results.
Average growth rate+430.37%
Beam Therapeutics Inc. had revenues for the full year 2023 of 377.71m. This was 520.01% above the prior year's results.
Average growth rate+54,121.88%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.